Influence of long-lasting administration of neuroleptics on cortical nmda receptors and phencyclidine-induced deficit in the sensorimotor gating in rats

Polish Journal of Pharmacology

Volumn 51, Issue 1, 1999, Pages 49-53

  Ossowska, Krystyna ^a   Pietraszek, Małgorzata ^a   Wardas, Jadwiga ^a   Nowak, Gabriel ^a   Wolfarth, Stanisław ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Cerebral cortex; Neuroleptics; NMDA receptors; Phencyclidine; Prepulse inhibition

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; CLOZAPINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; FRONTAL CORTEX; INSULA; NONHUMAN; ORAL DRUG ADMINISTRATION; PARIETAL LOBE; PREPULSE INHIBITION; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; SENSORIMOTOR FUNCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; CLOZAPINE; HALOPERIDOL; PHENCYCLIDINE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS;

EID: 0033010747     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bakshi V. P., Swerdlow N. R., Geyer M. A.: Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther., 1994, 271, 787-794.
2. Bunney B. G., Bunney W. E. Jr., Carlsson A.: Schizophrenia and glutamate. In: Psychopharmacology. The Fourth Generation of Progress. Eds. Bloom F. E., Kupfer D. J., Raven Press, Ltd., New York, 1995, 1205-1214.
3. Deakin J. F. W., Slater P., Simpson M. D. C., Gilchrist A. C., Skan W. J., Royston M. C., Reynolds G. P., Cross A. J.: Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem., 1989, 52, 1781-1786.
4. DeLisi L. E., Buchsbaum M. S., Holcomb H. H., Langsten K. C., King A. C., Kessler R., Pickar D., Carpenter W. T., Morihisa J. M., Margolin R., Weinberger D. R.: Increased temporal lobe glucose use in chronic schizophrenic patients. Biol. Psychiat., 1989, 25, 835-851.
5. Furuya Y., Ogura H.: Competitive NMDA and strychnine-insensitive glycine-site antagonists disrupt prepulse inhibition. Pharmacol. Biochem. Behav., 1997, 57, 909-913.
6. Gandolfi O., Dall'Olio R.: Modulatory role of dopamine on excitatory amino acid receptors. Prog. NeuroPsych. Biol. Psych., 1996, 20, 659-671.
7. Geyer M. A., Swerdlow N. R., Mansbach R. S., Braff D. L.: Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res. Bull., 1990, 25, 485-498.
8. Graham F. K.: The more or less startling effects of weak prestimuli. Psychophysiology, 1975, 12, 238-248.
9. Gur R. E., Resnick S. M., Alavi A., Gur R., Caroff S., Dann R., Saykin A. J., Chawluk J. B., Kushner M., Reivich M.: Regional brain function in schizophrenia. I: A positron emission tomography study. Arch. Gen. Psychiat., 1987, 44, 119-125.
10. Hoffman D. C., Donovan H., Cassella J. V.: The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology, 1993, 111, 339-314.
11. Ishimaru M., Kurumaji A., Toru M.: NMDA-associated glycine binding site increases in schizophrenic brains. Biol. Psychiat., 1992, 32, 379-381.
12. Johansson C., Jackson D. M., Svensson, L.: The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology, 1994, 116, 437-442.
13. Kahn R. S., Davis K. L.: New developments in dopamine and schizophrenia. In: Psychopharmacology. The Fourth Generation of Progress. Eds. Bloom F. E., Kupfer D. J., Raven Press, Ltd., New York, 1995, 1193-1201.
14. Keck P. E. Jr., Cowen B. M., Baldessarini R. J., McElroy S. L.: Time course of antipsychotic effects of neuroleptic drugs. Amer. J. Psychiat., 1989, 146, 1289-1292.
15. Keith V. A., Mansbach R. S., Geyer M. A.: Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol. Psychiat., 1991, 30, 557-566.
16. Kim J. S., Kornhuber H. H., Schmid-Burgk W., Holzmüller B.: Low cerebral fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett., 1980, 20, 379-382.
17. Korpi E. R., Kaufmann C. A., Marnela K. M., Weinberger D. R.: Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiat. Res., 1987, 20, 337-345.
18. Luisada P. V., Brown B. I.: Clinical management of the phencyclidine psychosis. Clin. Toxicol., 1976, 9, 539-545.
19. Mansbach R. S., Geyer M. A.: Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology, 1989, 2, 299-308.
20. Mansbach R. S., Geyer M. A., Braff D. L.: Dopaminergic stimulation disrupts sensorimotor gating. Psychopharmacology, 1988, 94, 507-514.
21. McCoy L., Richfield E. K.: Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci. Lett., 1996, 213, 137-141.
22. Meltzer H. Y., Stahl S. M.: The dopamine hypothesis of schizophrenia: a review. Schizophrenia Bull., 1976, 2, 19-76.
23. Olney J. W., Farber N. B.: NMDA antagonists as neurotherapeutic drugs, psychogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology, 1995, 13, 335-345.
24. Ossowska K., Pietraszek M., Wardas J., Nowak G., Wolfarth S.: Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn-Schmied. Arch. Pharmacol., submitted.
25. Perry T. L. : Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci. Lett., 1982, 28, 81-85.
26. Pietraszek M., Ossowska K.: Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats. Naunyn-Schmied. Arch. Pharmacol., 1998, 357, 466-471.
27. Rigdon G. C., Viik K.: Prepulse inhibition as a screening test for potential antipsychotics. Drug Develop. Res., 1991, 23, 91-99.
28. Roberts G. W.: Schizophrenia: the cellular biology of a functional psychosis. Trends Neurosci., 1990, 13, 207-211.
29. Schroeder J., Buchsbaum M. S., Siegel B. V., Geider F. J., Lohr J., Tang C., Wu J., Potkin S. G.: Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia. Schizophr. Res., 1996, 19, 41-53.
30. Seeman P.: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1987, 1, 133-152.
31. Sherman A. D., Davidson A. T., Barnah S., Hegwood T. S., Waziri R.: Evidence of glutamatergic deficiency in schizophrenia. Neurosci. Lett., 1991, 121, 77-80.
32. Siegel B. V., Buchsbaum M. S., Bunney W. E., Gottschalk L. A., Haier R. J., Lohr J. B., Lottenberg S., Najafi A., Nuechterlein K. H., Potkin S. G., Wu J. C.: Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Amer. J. Psychiat., 1993, 150, 1325-1336.
33. Simpson M. D. C., Slater P., Royston M. C., Deakin J. F. W.: Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effect of disease process and neuroleptic medication. Schizophr. Res., 1992, 6, 41-48.
34. Swerdlow N. R., Bakshi V., Geyer M. A.: Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Ther., 1996, 279, 1290-1299.
35. Swerdlow N. R., Keith V. A., Braff D. L., Geyer M. A.: Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J. Pharmacol. Exp. Ther., 1991, 256, 530-536.
36. Tarazi F. I., Florijn W. I., Creese I.: Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology, 1996, 128, 371-379.
37. Toru M., Kurumaji A., Kumashiro S., Suga I., Tamashima M., Nishikawa T.: Excitatory amino acidergic neurons in chronic schizophrenic brain. Mol. Neuropharmacol., 1992, 2, 241-243.
38. Toru M., Watanabe S., Shibuya H., Nishikawa T., Noda K., Mitsushio H., Ichikawa H., Kurumaji A., Takashima M., Mataga N., Ogawa A.: Neurotransmitters, receptors and neuropeptides in postmortem brains of chronic schizophrenic patients. Acta Psychiat. Scand., 1988, 78, 121-137.
39. Tsai G., Passani L. A., Slusher B. S., Carter R., Baer L., Kleinman J. E., Coyle J. T.: Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiat., 1995, 52, 829-836.
40. Ułas J, Nguyen L., Cotman C. W.: Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. NeuroReport, 1993, 4, 1049-1051.
41. Wȩdzony K., Gołembiowska K., Zazula M.: Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn Schmied. Arch. Pharmacol., 1994, 350, 555-562.